Skip to main content
Midas Edge

Stoke Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

STOK$27.21-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed consolidated statements of stockholders’ equity

Common Stock · Additionalpaid-in capital · Accumulated other comprehensive gain (loss) · Accumulateddeficit · Total stockholders’equity
Shares · Amount
Balance as of December 31, 202454,032,826$5$719,997$(151)$(490,830)$229,021
Unrealized gain on marketable securities———47—47
Stock-based compensation——6,753——6,753
Issuance of common stock upon exercise of stock options214,996—1,004——1,004
Issuance of common stock related to employee stock purchase plan39,467—370——370
Issuance of vested restricted and performance stock units308,425—————
Net income————112,879112,879
Balance as of March 31, 202554,595,714$5$728,124$(104)$(377,951)$350,074
Unrealized gain on marketable securities———200—200
Stock-based compensation——7,598——7,598
Issuance of common stock upon exercise of stock options126,531—554——554
Issuance of vested restricted and performance stock units1,210—————
Net loss————(23,483)(23,483)
Balance as of June 30, 202554,723,455$5$736,276$96$(401,434)$334,943
Unrealized gain on marketable securities———350—350
Stock-based compensation——8,039——8,039
Issuance of common stock upon exercise of stock options262,320—2,488——2,488
Issuance of vested restricted and performance stock units68,210—————
Issuance of common stock related to employee stock purchase plan66,017—632——632
Net loss————(38,347)(38,347)
Balance as of September 30, 202555,120,002$5$747,435$446$(439,781)$308,105

Condensed consolidated statements of stockholders’ equity

Common Stock · Additionalpaid-in capital · Accumulated other comprehensive gain (loss) · Accumulateddeficit · Total stockholders’equity
Shares · Amount
Balance as of December 31, 202558,921,999$5$849,624$543$(497,715)$352,457
Unrealized (loss) on marketable securities———(658)—(658)
Stock-based compensation——8,753——8,753
Issuance of common stock upon exercise of stock options260,554—3,205——3,205
Issuance of common stock related to employee stock purchase plan46,994465——465
Issuance of vested restricted and performance stock units443,786—————
Shares sold as part of controlled equity offering sales agreement2,567,014180,657——80,658
Net loss————(50,003)(50,003)
Balance as of March 31, 202662,240,347$6$942,704$(115)$(547,718)$394,877
Unrealized (loss) on marketable securities———(427)—(427)
Stock-based compensation——10,802——10,802
Issuance of common stock upon exercise of stock options162,248—1,913——1,913
Net loss————(61,618)(61,618)
Balance as of June 30, 202662,402,595$6$955,419$(542)$(609,336)$345,547
Unrealized (loss) on marketable securities———(508)—(508)
Stock-based compensation——11,033——11,033
Issuance of common stock upon exercise of stock options264,109—3,525——3,525
Issuance of vested restricted and performance stock units61,000—————
Issuance of common stock related to employee stock purchase plan35,833—941——941
Shares sold as part of controlled equity offering sales agreement2,050,000—65,694——65,694
Net loss————(73,644)(73,644)
Balance as of September 30, 202664,813,537$6$1,036,612$(1,050)$(682,980)$352,588
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.